Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet in Stroke Patients Patients

Criteria the registry did not label

• Inclusion Criteria
• Men and women, 55 years of age - inclusive- or older
• Acute stroke as defined by an acute focal neurological deficit in combination with one of the following: acute ischemic infarct (stroke) as documented by either a DWl positive lesion on MR imaging or a new lesion on a delayed CT scan
• Written informed consent by patient prior to study participation
• Willingness to complete all assessments and participate in follow-up
• Willing to participate and give informed consent
• Adequate Visual and auditory acuity to undergo neuropsychological testing
• Exclusion criteria
• CDR\>=0.5
• Nuts, berries, olive oil, or fish allergies
• Use of medications to treat Alzheimer's disease or Parkinson's disease
• Aphasia
• Conditions of psychosis or bipolar disorder judged by study investigators to potentially interfere with study compliance over 3 years
• Report of alcohol or substance abuse within six months, or heavy alcohol consumption (\>2 drinks/d women; \>3 drinks/d men)
• Unstable or recent onset of cardiovascular disease, such as myocardial infarction within six months or presence of congestive heart failure (Stages II-IV)
• Cancer treatment \<= 5 years except non-melanoma skin cancer , basal cell skin cancer (this criterion may be waived at the site PI's discretion)
• Illness that might be associated with weight change, such as a history of stomach or gastrointestinal conditions (Inflammatory Bowel Disease, Crohn's Disease, malabsorption, colostomy, bowel resection, gastric bypass surgery, etc.)
• History of liver disease, HIV or Hepatitis C
• An intracerebral hemorrhage as documented on CT or MRI
• Pre- hospitalization diagnosis of dementia or mild cognitive impairment
• Patients presenting one of the following diseases: cerebral venous thrombosis, traumatic cerebral hemorrhage, intracerebral hemorrhage because of a known or image-guided assumed vascular malformation, pure meningeal or intraventricular hemorrhage
• Patients presenting a malignant disease with life expectancy \< 3 years
• Residence in a nursing home and thus going back to nursing home upon discharge
• Participation in an ongoing investigational drug study
• Exception to these guidelines will be rare but may be considered on a case by case basis at the discretion of the PI's